CN107074942A - 抗‑IL‑1β抗体和使用方法 - Google Patents

抗‑IL‑1β抗体和使用方法 Download PDF

Info

Publication number
CN107074942A
CN107074942A CN201580060880.4A CN201580060880A CN107074942A CN 107074942 A CN107074942 A CN 107074942A CN 201580060880 A CN201580060880 A CN 201580060880A CN 107074942 A CN107074942 A CN 107074942A
Authority
CN
China
Prior art keywords
antibody
amino acid
human
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580060880.4A
Other languages
English (en)
Chinese (zh)
Inventor
斯特凡·登格尔
彼得·迈克尔·许尔斯曼
克里斯蒂安·加斯纳
塞巴斯蒂安·布罗伊尔
奥拉夫·蒙迪戈
盖伊·乔治
拉尔夫·舒马赫
古伊多·哈特曼
扎比内·格吕纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107074942A publication Critical patent/CN107074942A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580060880.4A 2014-11-10 2015-11-06 抗‑IL‑1β抗体和使用方法 Pending CN107074942A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192523 2014-11-10
EP14192523.0 2014-11-10
PCT/EP2015/075875 WO2016075034A1 (en) 2014-11-10 2015-11-06 ANTI-IL-1beta ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CN107074942A true CN107074942A (zh) 2017-08-18

Family

ID=51868114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580060880.4A Pending CN107074942A (zh) 2014-11-10 2015-11-06 抗‑IL‑1β抗体和使用方法

Country Status (15)

Country Link
US (1) US10344085B2 (enExample)
EP (1) EP3218402A1 (enExample)
JP (1) JP6787888B2 (enExample)
KR (1) KR20170081253A (enExample)
CN (1) CN107074942A (enExample)
AR (1) AR102594A1 (enExample)
AU (1) AU2015345320A1 (enExample)
BR (1) BR112017009817A2 (enExample)
CA (1) CA2963719A1 (enExample)
IL (1) IL251165A0 (enExample)
MX (1) MX2017005987A (enExample)
RU (1) RU2017120358A (enExample)
SG (1) SG11201702550WA (enExample)
TW (1) TW201632552A (enExample)
WO (1) WO2016075034A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020034941A1 (zh) * 2018-08-14 2020-02-20 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN111662381A (zh) * 2019-03-07 2020-09-15 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
CN117126278A (zh) * 2023-10-26 2023-11-28 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
BR112017009792A2 (pt) 2014-11-10 2018-02-27 Hoffmann La Roche anticorpos anti-pdgf-b e métodos de uso
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
KR102087823B1 (ko) * 2017-05-16 2020-03-13 에이치케이이노엔 주식회사 친화성 크로마토그래피를 이용한 항체 또는 항체절편 정제 방법
WO2018212556A1 (en) * 2017-05-16 2018-11-22 Cj Healthcare Corporation A method for purifying an antibody or an antibody fragment thereof using affinity chromatography
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
AR117468A1 (es) * 2018-12-21 2021-08-11 Hoffmann La Roche ANTICUERPO QUE SE UNE A VEGF Y A IL-1b Y MÉTODOS DE UTILIZACIÓN
MX2021015356A (es) * 2019-06-11 2022-04-06 Bioatla Inc Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
WO2004067568A2 (en) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
CN102369217A (zh) * 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
CN102655880A (zh) * 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
CN103517921A (zh) * 2010-12-21 2014-01-15 Abbvie公司 IL-1-α和-β双特异性双重可变结构域免疫球蛋白及其用途
US20140271458A1 (en) * 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17
WO2014177460A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003208946A1 (en) * 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN104474546A (zh) * 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
RU2013115927A (ru) * 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
JP6069312B2 (ja) 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
WO2014049100A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JP6345787B2 (ja) 2013-12-20 2018-06-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
BR112017009792A2 (pt) 2014-11-10 2018-02-27 Hoffmann La Roche anticorpos anti-pdgf-b e métodos de uso
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
CA3061053A1 (en) 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
WO2004067568A2 (en) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
CN102369217A (zh) * 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
CN102655880A (zh) * 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
CN103517921A (zh) * 2010-12-21 2014-01-15 Abbvie公司 IL-1-α和-β双特异性双重可变结构域免疫球蛋白及其用途
US20140271458A1 (en) * 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17
WO2014177460A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUAN C. ALMAGRO等: ""Humanization of antibodies"", 《FRONTIERS IN BIOSCIENCE》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020034941A1 (zh) * 2018-08-14 2020-02-20 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN112654640A (zh) * 2018-08-14 2021-04-13 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
US12286473B2 (en) 2018-08-14 2025-04-29 Akeso Biopharma, Inc. Anti-IL-1β antibody and pharmaceutical composition thereof and use of same
CN111662381A (zh) * 2019-03-07 2020-09-15 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
CN111662381B (zh) * 2019-03-07 2022-06-07 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
CN115028723A (zh) * 2019-03-07 2022-09-09 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
CN115028723B (zh) * 2019-03-07 2023-08-29 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
CN117126278A (zh) * 2023-10-26 2023-11-28 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用
CN117126278B (zh) * 2023-10-26 2024-01-05 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Also Published As

Publication number Publication date
JP2017534646A (ja) 2017-11-24
TW201632552A (zh) 2016-09-16
RU2017120358A3 (enExample) 2019-05-29
IL251165A0 (en) 2017-04-30
EP3218402A1 (en) 2017-09-20
CA2963719A1 (en) 2016-05-19
US10344085B2 (en) 2019-07-09
WO2016075034A1 (en) 2016-05-19
AU2015345320A1 (en) 2017-04-06
JP6787888B2 (ja) 2020-11-18
MX2017005987A (es) 2017-06-29
SG11201702550WA (en) 2017-04-27
BR112017009817A2 (pt) 2018-02-14
US20170247447A1 (en) 2017-08-31
AR102594A1 (es) 2017-03-08
RU2017120358A (ru) 2018-12-13
KR20170081253A (ko) 2017-07-11

Similar Documents

Publication Publication Date Title
US10344085B2 (en) Anti-IL-1beta antibodies
US10730938B2 (en) Bispecific antibodies and methods of use in ophthalmology
ES2791989T3 (es) Anticuerpos humanizados anti-CD19 humano y procedimientos de uso
US10087246B2 (en) Anti-PDGF-B antibodies and methods of use
KR20150030755A (ko) 항-바이오틴 항체 및 사용 방법
US20170247441A1 (en) Anti-ang2 antibodies and methods of use
JP6549278B2 (ja) 抗テオフィリン抗体および使用方法
US20240327522A1 (en) Anti-alpha v beta 8 integrin antibodies and methods of use
HK1238257A1 (en) Anti-il-1beta antibodies and methods of use
HK1236207A1 (en) Bispecific antibodies and methods of use in ophthalmology
HK1242354B (zh) 抗茶碱抗体及使用方法
HK1239711B (zh) 抗-pdgf-b抗体和使用方法
HK1239711A1 (en) Anti-pdgf-b antibodies and methods of use
HK1208235B (zh) 抗生物素抗体及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238257

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1238257

Country of ref document: HK